UTMD

Business Context and Reporting Period

Company: Utah Medical Products, Inc. (UTMD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2005
Business Overview: UTMD manufactures and markets specialty medical devices, including products for labor & delivery, neonatal care, gynecology, electrosurgery, and urology. The company operates manufacturing facilities in the U.S. and Ireland.

Key Financial Metrics

Note: The company reported no debt and no interest expense during the periods presented.

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 5% in Q3 2005 and 3% for the nine months ended September 30, 2005, compared to the prior year. Neonatal sales surged 72% in Q3 2005, partially due to a competitor's temporary product withdrawal.
• Profitability Decline: Net income for the nine months dropped 36% to $5.6 million from $8.8 million in the prior year. This decline is primarily attributed to the absence of a one-time $5.7 million operating income gain from a patent infringement lawsuit settlement recognized in Q1 2004.
• Operating Expenses: Operating expenses increased significantly in Q3 2005 due to $706,000 in litigation costs associated with an FDA lawsuit. Conversely, 2004 expenses were artificially low due to the aforementioned patent settlement income.
• Cash Flow: Operating cash flow for the nine months decreased to $4.6 million from $26.3 million in the prior year, largely due to the non-recurring litigation settlement receipt in 2004.
• Share Repurchases: The company repurchased 299,099 shares for $6.5 million during the nine months of 2005, reducing the share count and supporting EPS.

Guidance, Outlook, and Risks

• Legal Resolution: On October 21, 2005, a U.S. District Court ruled in favor of UTMD, dismissing all FDA allegations regarding Quality System Regulation (QSR) compliance. This resolves a long-standing regulatory uncertainty that had hindered business development.
• Tax Benefits: The company benefited from a lower effective tax rate in 2005 due to the American Jobs Creation Act of 2004, allowing for a temporary deduction on repatriated foreign earnings. This is a non-recurring benefit limited to 2005.
• Accounting Changes: UTMD anticipates adopting SFAS 123(R) in Q1 2006, which will require recognizing stock-based compensation expense. Management estimates this will result in approximately $150,000 in additional expense for 2006 related to currently outstanding options.
• Outlook: Management plans to utilize cash balances for selective acquisitions, continued share repurchases, and litigation expenses. Capital expenditures for the remainder of 2005 are expected to be approximately $200,000.
• Risks: Key risks include market acceptance of competitive products, regulatory approvals for new products, and foreign currency fluctuations (Euro/USD) affecting Irish operations.

Investor Verification Checklist

• Recurring Profitability: Verify if operating margins can sustain levels seen in Q3 2005 (29.1%) without the one-time litigation costs that inflated 2004 results.
• Neonatal Sales Sustainability: Confirm if the 72% increase in neonatal sales is a permanent shift in market share or a temporary benefit from a competitor's product withdrawal.
• Stock-Based Compensation Impact: Monitor Q1 2006 earnings for the impact of SFAS 123(R) adoption on net income and EPS.
• Share Count Reduction: Track the effectiveness of the ongoing share repurchase program in offsetting dilution from employee stock options.
• Regulatory Status: Confirm that the October 2005 court victory has fully restored the company's ability to pursue new product development and business development without FDA impediments.